In a single-blind phase II trial in 132 patients with birch pollen allergy, up to five pre-seasonal monthly injections of the recombinant vaccine GNR-127 reduced the combined symptom medication score versus placebo by 17.41% (40 μg) and 24.13% (80 μg), significant only at 80 μg.
RCTn = 132
Khaitov et al. Pre-Seasonal Treatment With Recombinant Carrier-Based Birch Vaccine Improves Birch Pollen Allergy